Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure
| Autor: | Jessica Clima, Ghulam Sajjad, Naomi Galili, Fahd Quddus, Azra Raza, Helen Seedham |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Anemia Population Administration Oral Case Report Antineoplastic Agents Lower risk lcsh:RC254-282 Gastroenterology Hemoglobins Erythroid Cells Internal medicine medicine Humans education Lenalidomide Molecular Biology Aged education.field_of_study Hematology lcsh:RC633-647.5 business.industry Myelodysplastic syndromes Remission Induction lcsh:Diseases of the blood and blood-forming organs lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Glutathione Hematologic Response Thalidomide Treatment Outcome Oncology Chromosomes Human Pair 2 Myelodysplastic Syndromes Immunology Chromosomes Human Pair 5 Chromosomes Human Pair 3 Chromosome Deletion business medicine.drug |
| Zdroj: | Journal of Hematology & Oncology Journal of Hematology & Oncology, Vol 3, Iss 1, p 16 (2010) |
| ISSN: | 1756-8722 |
| Popis: | Treatment options for patients with lower risk non-del(5q) myelodysplastic syndromes (MDS) who fail erythroid stimulating agents are restricted to one of the hypomethylating drugs with an expected response rate of ~50%. Ezatiostat HCl, an agent with the potential for producing multi-lineage responses in this population is currently in clinical investigation phase. This case report describes a 77 year old male who received less than two cycles of therapy with ezatiostat HCl which had to be aborted due to intolerable side effects, but which produced a sustained normalization of all three blood counts. This trilineage response has now lasted for more than a year. Interestingly, the patient began with a del(5q) abnormality and responded briefly to lenalidomide. Upon relapse of the anemia, a bone marrow showed the disappearance of the del(5q) but the appearance of a new clonal abnormality t(2;3). Given that the patient had a complete cytogenetic response to a truncated exposure to lenalidomide followed by a trilineage response to an even briefer course of ezatiostat HCl suggests a potential role for ezatiostat HCl in del(5q) patients who relapse following lenalidomide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|